JNJ

153.37

+0.64%↑

ABBV

185.36

+1.38%↑

NVO

69.45

+1.17%↑

UNH

298.13

+0.31%↑

ABT

132.76

+0.59%↑

JNJ

153.37

+0.64%↑

ABBV

185.36

+1.38%↑

NVO

69.45

+1.17%↑

UNH

298.13

+0.31%↑

ABT

132.76

+0.59%↑

JNJ

153.37

+0.64%↑

ABBV

185.36

+1.38%↑

NVO

69.45

+1.17%↑

UNH

298.13

+0.31%↑

ABT

132.76

+0.59%↑

JNJ

153.37

+0.64%↑

ABBV

185.36

+1.38%↑

NVO

69.45

+1.17%↑

UNH

298.13

+0.31%↑

ABT

132.76

+0.59%↑

JNJ

153.37

+0.64%↑

ABBV

185.36

+1.38%↑

NVO

69.45

+1.17%↑

UNH

298.13

+0.31%↑

ABT

132.76

+0.59%↑

Search

Eli Lilly and Co.

Chiusa

SettoreSettore sanitario

720.79 0.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

716.63

Massimo

727

Metriche Chiave

By Trading Economics

Entrata

-6.1B

2.8B

Vendite

-804M

13B

P/E

Media del settore

58.12

53.54

EPS

3.34

Rendimento da dividendi

0.84

Margine di Profitto

21.678

Dipendenti

47,000

EBITDA

-2B

4.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+39.44% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.84%

2.44%

Utili prossimi

6 ago 2025

Prossima data del Dividendo

10 giu 2025

Prossima data del' Ex Dividendo

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-187B

641B

Apertura precedente

720.37

Chiusura precedente

720.79

Notizie sul Sentiment di mercato

By Acuity

29%

71%

81 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Eli Lilly and Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mag 2025, 14:41 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1 mag 2025, 11:24 UTC

Utili

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29 mag 2025, 01:00 UTC

Notizie principali

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New -2-

28 mag 2025, 18:09 UTC

Utili

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mag 2025, 14:02 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mag 2025, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mag 2025, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mag 2025, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mag 2025, 14:08 UTC

Utili

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 18:45 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mag 2025, 17:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mag 2025, 17:01 UTC

Notizie principali

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mag 2025, 13:56 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mag 2025, 11:18 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mag 2025, 09:30 UTC

Notizie principali

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mag 2025, 20:30 UTC

Notizie principali

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mag 2025, 04:05 UTC

Acquisizioni, Fusioni, Takeovers

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mag 2025, 21:07 UTC

Discorsi di Mercato

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mag 2025, 14:07 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 12:47 UTC

Utili

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 mag 2025, 12:00 UTC

Notizie principali

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 mag 2025, 11:58 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 11:06 UTC

Utili

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mag 2025, 10:48 UTC

Utili

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 mag 2025, 10:48 UTC

Utili

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 mag 2025, 10:45 UTC

Utili

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 mag 2025, 10:45 UTC

Utili

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 mag 2025, 10:45 UTC

Utili

Eli Lilly 1Q Net $2.76B >LLY

Confronto tra pari

Modifica del prezzo

Eli Lilly and Co. Previsione

Obiettivo di Prezzo

By TipRanks

39.44% in crescita

Previsioni per 12 mesi

Media 1,003.14 USD  39.44%

Alto 1,190 USD

Basso 700 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

16

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 884.54Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

81 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.